Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
Nicola Specchio, Nicola Pietrafusa, Marina Trivisano Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome, ItalyCorrespondence: Nicola SpecchioDepartment of Neuroscience, Bambino Gesù Children’s Hospital,...
Saved in:
Main Authors: | Specchio N (Author), Pietrafusa N (Author), Trivisano M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
by: Aryun Kim, et al.
Published: (2021) -
Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease
by: Samantha J. Murray, et al.
Published: (2023) -
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
by: Goker-Alpan O, et al.
Published: (2016) -
Enzyme replacement therapy: efficacy and limitations
by: Daniela Concolino, et al.
Published: (2018) -
Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease
by: V. I. Ignatyeva, et al.
Published: (2019)